Pharmaceutical Regulatory Affairs: Open Access

Tapan Kumar Pal

Publications

• Review Article
  “New Drugs and Clinical Trials Rules-2018” (GSR-104 E) by CDSCO: It’s Impact on BA/BE Studies in India
  Author(s): Shubhasis Dan, Anirbandeep Bose, Balaram Ghosh, Pallab Mandal and Tapan Kumar PalShubhasis Dan, Anirbandeep Bose, Balaram Ghosh, Pallab Mandal and Tapan Kumar Pal
  
  India is the largest provider of generic drugs globally with the Indian generics accounting for 20% of global exports in terms of volume. Comparative pharmacokinetic data under the regulatory framework of bioavailability and bioequivalence (BA/BE) study data is widely accepted by the developed countries regulatory agencies over last 4 decades to establish the efficacy of the generic products. Ministry of Health and Family Welfare, Government of India recently published the ‘New Drugs and Clinical Trials Rules-2018’ vide gazette notification (GSR-104E) dated 01/02/2018. An elaborate and streamlined regulations for conducting clinical research (CT and BA/BE studies) in India has been provided in the said draft rule. It was available in the public doma.. Read More»
  

  Abstract PDF